In pre-clinical models, synthetic lethality between ROS1 inhibition in E-cadherin deficient cells has been demonstrated, characterized by antitumor effects on E-cadherin deficient breast cancer cells in vivo after the administration of ROS1 inhibitors (such as crizotinib and foretinib)24. The gene discussed is ROS1; the disease is breast cancer.